I would say it’s imaging.
I hope this helped : )
Have a nice day
The insulin which a nurse will administer to an intermediate-acting insulin patient with diabetes is NPH ( Neutral Protamine Hagedorn )
Please get this clear that this NPH insulin is a special type of insulin injection which is usually, frequently and most of the time given to patients with health problems such as diabetes in order help them control blood sugar levels.
<h3>Diabetes</h3>
Diabetes is an health condition which is characterized by the presence of too much of glucose or sugar in the blood. Individuals with diabetes however must seek quality and adequate healthcare services in order improve or cure the condition
So therefore, the insulin which a nurse will administer to an intermediate-acting insulin patient with diabetes is NPH insulin ( Neutral Protamine Hagedorn )
<h3>Complete question:</h3>
The nurse is preparing to administer intermediate-acting insulin to a patient with diabetes. Which insulin will the nurse administer?
a. NPH
b. Iletin II
c. Humalog (lispro)
d. Glargine (lantus)
Learn more about health problems:
brainly.com/question/1382377
#SPJ1
Antioxidant therapy for pain reduction in patients with chronic pancreatitis: a systematic review and meta-analysis.
<h3>Objectives:</h3>
- Oxidative stress is strongly implicated in the pathogenesis of chronic pancreatitis (CP); however, clinical studies evaluating antioxidant therapy (AOT) in the management of CP pain have yielded conflicting results.
- The aim of this meta-analysis was to evaluate the efficacy of AOT in pain reduction in CP patients.
<h3>Methods: </h3>
- From the beginning until December 2013, two writers separately performed a thorough literature search.
- The Mantel-Haenszel and DerSimonian-Laird techniques were used to compute the relative risk (RR) and 95% confidence intervals (CIs).
<h3>Results: </h3>
- There were eight studies totaling 446 patients (234 in the AOT group and 212 in the control group).
- Overall, compared to the control group, CP patients who received AOT saw a substantial decrease in pain (RR, 0.73; 95% CI, 0.58-0.91; P = 0.006).
- Trials with primarily alcoholic CP patients (RR, 0.60; 95% CI, 0.47-0.77; P 0.0001) and studies with patients who were on average 42 years old or older (RR, 0.66; 95% CI, 0.49-0.89; P = 0.006) also shown a substantial advantage of AOT over placebo in the subgroup analysis.
<h3>Conclusions: </h3>
- This is the first meta-analysis to compile all the evidence that is currently available and demonstrate the value of AOT in reducing pain in CP patients.
- To better identify the patient and illness characteristics favoring response, the ideal formulation, and the duration of AOT, larger studies with longer follow-up are urgently needed.
To learn more about antioxidants visit:
brainly.com/question/15365788
#SPJ4
